{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:11:02Z","timestamp":1770459062397,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIL","award":["NIL"],"award-info":[{"award-number":["NIL"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anemia affects one-third of heart failure patients and is associated with increased morbidity and mortality. Despite being one of the commonest comorbidities associated with heart failure, there is a significant knowledge gap about management of anemia in the setting of heart failure due to conflicting evidence from recent trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>The etiology of anemia in heart failure is multifactorial, with absolute and functional iron deficiency, decreased erythropoietin levels and erythropoietin resistance, inflammatory state and heart failure medications being the important causative factors. Anemia adversely affects the already compromised hemodynamics in heart failure, besides being commonly associated with more comorbidities and more severe disease. Though low hemoglobin levels are associated with poor outcomes, the correction of anemia has not been consistently associated with improved outcomes. Parenteral iron improves the functional capacity in iron deficient heart failure patients, the effects are independent of hemoglobin levels, and also the evidence on hard clinical outcomes is yet to be ascertained.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Despite all the research, anemia in heart failure remains an enigma. Perhaps, anemia is a marker of severe disease, rather than the cause of poor outcome in these patients. In this review, we discuss the current understanding of anemia in heart failure, its management and the newer therapies being studied.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-021-00200-6","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T13:02:44Z","timestamp":1630155764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Anemia in heart failure: still an unsolved enigma"],"prefix":"10.1186","volume":"73","author":[{"given":"Yash Paul","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navjyot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Kasinadhuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Batta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pulkit","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samman","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-5209","authenticated-orcid":false,"given":"Prashant","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"issue":"6","key":"200_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","volume":"13","author":"B Ziaeian","year":"2016","unstructured":"Ziaeian B, Fonarow GC (2016) Epidemiology and aetiology of heart failure. Nat Rev Cardiol 13(6):368\u2013378","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"200_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hfc.2016.07.001","volume":"13","author":"JA Mazurek","year":"2017","unstructured":"Mazurek JA, Jessup M (2017) Understanding Heart Failure. Heart Fail Clin 13(1):1\u201319","journal-title":"Heart Fail Clin"},{"key":"200_CR3","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al; American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 128(16):e240\u2013327."},{"issue":"1","key":"200_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ehf2.12005","volume":"1","author":"P Ponikowski","year":"2014","unstructured":"Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S et al (2014) eart failure: preventing disease and death worldwide. ESC Heart Fail 1(1):4\u201325","journal-title":"ESC Heart Fail"},{"issue":"9","key":"200_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrcardio.2011.77","volume":"8","author":"DJ van Veldhuisen","year":"2011","unstructured":"van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC (2011) Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 8(9):485\u2013493","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"200_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacc.2011.10.864","volume":"59","author":"B Waldum","year":"2012","unstructured":"Waldum B, Westheim AS, Sandvik L, Flon\u00e6s B, Grundtvig M, Gullestad L et al (2012) Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. J Am Coll Cardiol 59(4):371\u2013378","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"200_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jchf.2017.08.023","volume":"6","author":"N Grote Beverborg","year":"2018","unstructured":"Grote Beverborg N, van Veldhuisen DJ, van der Meer P (2018) Anemia in Heart Failure: Still Relevant? JACC Heart Fail 6(3):201\u2013208","journal-title":"JACC Heart Fail"},{"key":"200_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","volume":"138","author":"IS Anand","year":"2018","unstructured":"Anand IS, Gupta P (2018) Anemia and iron deficiency in heart failure. Circulation 138:80\u201398","journal-title":"Circulation"},{"key":"200_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.04.044","volume":"52","author":"IS Anand","year":"2008","unstructured":"Anand IS (2008) Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 52:501\u2013511","journal-title":"J Am Coll Cardiol"},{"key":"200_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1161\/01.CIR.0000052622.51963.FC","volume":"107","author":"JA Ezekowitz","year":"2003","unstructured":"Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation 107:223\u2013225","journal-title":"Circulation"},{"key":"200_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ajh.23598","volume":"89","author":"LT Goodnough","year":"2014","unstructured":"Goodnough LT, Schrier SL (2014) Evaluation and management of anemia in the elderly. Am J Hematol 89:88\u201396","journal-title":"Am J Hematol"},{"key":"200_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1161\/CIRCULATIONAHA.104.512988","volume":"112","author":"IS Anand","year":"2005","unstructured":"Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A et al (2005) Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112:1121\u20131127","journal-title":"Circulation"},{"key":"200_CR13","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/eurheartj\/ehi388","volume":"26","author":"C Opasich","year":"2005","unstructured":"Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R et al (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26:2232\u20132237","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"200_CR14","first-page":"485","volume":"27","author":"IS Anand","year":"2006","unstructured":"Anand IS, Rector T, Deswal A, Iverson E, Anderson S, Mann D et al (2006) Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J 27(suppl 1):485","journal-title":"Eur Heart J"},{"issue":"10","key":"200_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","volume":"52","author":"HF Groenveld","year":"2008","unstructured":"Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ et al (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52(10):818\u2013827","journal-title":"J Am Coll Cardiol"},{"key":"200_CR16","doi-asserted-by":"publisher","first-page":"770","DOI":"10.7326\/0003-4819-159-11-201312030-00009","volume":"159","author":"A Qaseem","year":"2013","unstructured":"Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P (2013) Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 159:770\u2013779","journal-title":"Ann Intern Med"},{"key":"200_CR17","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.jacc.2019.08.001","volume":"74","author":"SM Hollenberg","year":"2019","unstructured":"Hollenberg SM, Warner Stevenson L, Ahmad T, Amin VJ, Bozkurt B, Butler J et al (2019) 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 74:1966\u20132011","journal-title":"J Am Coll Cardiol"},{"key":"200_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ahj.2009.08.001","volume":"158","author":"M Garty","year":"2009","unstructured":"Garty M, Cohen E, Zuchenko A et al (2009) Blood transfusion for acute decompensated heart failure\u2014friend or foe? Am Heart J 158:653\u2013658","journal-title":"Am Heart J"},{"key":"200_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2010.08.046","volume":"107","author":"DP Kao","year":"2011","unstructured":"Kao DP, Kreso E, Fonarow GC, Krantz MJ (2011) Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000\u20132006). Am J Cardiol 107:69\u201373","journal-title":"Am J Cardiol"},{"issue":"13","key":"200_CR20","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","volume":"368","author":"K Swedberg","year":"2013","unstructured":"Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al (2013) RED-HF committees; RED-HF investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210\u20131219","journal-title":"N Engl J Med"},{"key":"200_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jacc.2004.03.052","volume":"44","author":"P van der Meer","year":"2004","unstructured":"van der Meer P, Voors AA, Lipsic E, Smilde TDJ, van Gilst WH, van Veldhuisen DJ (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44:63\u201367","journal-title":"J Am Coll Cardiol"},{"key":"200_CR22","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"2017","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al (2017) ACCF\/ACC\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guidelines for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017:776\u2013803","journal-title":"J Am Coll Cardiol"},{"key":"200_CR23","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. ESC Scientific Document Group (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129\u20132200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"200_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ejhf.1531","volume":"21","author":"PM Seferovic","year":"2019","unstructured":"Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21:1169\u20131186","journal-title":"Eur J Heart Fail"},{"key":"200_CR25","doi-asserted-by":"crossref","unstructured":"Anker SD, Comin-Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, FAIR-HF Investigators et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436\u20132348.","DOI":"10.1056\/NEJMoa0908355"},{"key":"200_CR26","doi-asserted-by":"crossref","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, CONFIRM-HF Investigators et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020. Eur Heart J 36(11):657\u2013668.","DOI":"10.1093\/eurheartj\/ehu385"},{"key":"200_CR27","doi-asserted-by":"crossref","unstructured":"van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, B\u00f6hm M, Doletsky A, EFFECT-HF Investigators et al (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 136(15):1374\u20131383","DOI":"10.1161\/CIRCULATIONAHA.117.027497"},{"key":"200_CR28","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, AFFIRM-AHF investigators, et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895\u20131904.","DOI":"10.1016\/S0140-6736(20)32339-4"},{"key":"200_CR29","first-page":"20","volume":"19","author":"N Grote Beverborg","year":"2017","unstructured":"Grote Beverborg N, van der Meer P (2017) Definition of iron deficiency based on the gold standard of bone marrow iron staining and treatment effect of ferric carboxymaltose in heart failure patients (abstr). Eur J Heart Fail 19:20\u201321","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"200_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ejhf.823","volume":"20","author":"SD Anker","year":"2018","unstructured":"Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F et al (2018) Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 20(1):125\u2013133","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"200_CR31","doi-asserted-by":"publisher","first-page":"e000345","DOI":"10.1161\/CIRCHEARTFAILURE.115.000345","volume":"9","author":"GD Lewis","year":"2016","unstructured":"Lewis GD, Semigran MJ, Givertz MM, Malhotra R, Anstrom KJ, Hernandez AF et al (2016) Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure. Circ Heart Fail 9(5):e000345","journal-title":"Circ Heart Fail"},{"issue":"5","key":"200_CR32","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1164\/ajrccm.155.5.9154866","volume":"155","author":"PC H\u00e9bert","year":"1997","unstructured":"H\u00e9bert PC, Wells G, Tweeddale M, Martin C, Marshall J, Pham B et al (1997) Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med 155(5):1618\u20131623","journal-title":"Am J Respir Crit Care Med"},{"key":"200_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/00003246-200102000-00001","volume":"29","author":"PC Hebert","year":"2001","unstructured":"Hebert PC, Yetisir E, Martin C et al (2001) Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 29:227\u2013234","journal-title":"Crit Care Med"},{"issue":"6","key":"200_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJM199902113400601","volume":"340","author":"PC Hebert","year":"1999","unstructured":"Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G et al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care (TRICC)investigators. Canadian critical care trials group. N Engl J Med 340(6):409\u2013417","journal-title":"N Engl J Med"},{"key":"200_CR35","doi-asserted-by":"crossref","unstructured":"Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group (2008) Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117(4):526\u2013535.","DOI":"10.1161\/CIRCULATIONAHA.107.698514"},{"issue":"1","key":"200_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","volume":"10","author":"S Vadhan-Raj","year":"2017","unstructured":"Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL Jr et al (2017) A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol 10(1):73","journal-title":"J Hematol Oncol"},{"issue":"17","key":"200_CR37","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/blood-2014-03-559484","volume":"124","author":"LT van Eijk","year":"2014","unstructured":"van Eijk LT, John AS, Schwoebel F, Summo L, Vaul\u00e9on S, Z\u00f6llner S et al (2014) Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 124(17):2643\u20132646","journal-title":"Blood"},{"issue":"4","key":"200_CR38","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nm.3524","volume":"20","author":"RF Paulson","year":"2014","unstructured":"Paulson RF (2014) Targeting a new regulator of erythropoiesis to alleviate anemia. Nat Med 20(4):334\u2013335","journal-title":"Nat Med"},{"issue":"2","key":"200_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","volume":"41","author":"C Iancu-Rubin","year":"2013","unstructured":"Iancu-Rubin C, Mosoyan G, Wang J, Kraus T, Sung V, Hoffman R (2013) Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 41(2):155-166.e17","journal-title":"Exp Hematol"},{"key":"200_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0959-437X(98)80016-6","volume":"8","author":"GL Semenza","year":"1998","unstructured":"Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8:588\u2013594","journal-title":"Curr Opin Genet Dev"},{"issue":"8","key":"200_CR41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","volume":"32","author":"N Chen","year":"2017","unstructured":"Chen N, Qian J, Chen J, Yu X, Mei C, Hao C et al (2017) Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant 32(8):1373\u20131386","journal-title":"Nephrol Dial Transplant"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00200-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-021-00200-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00200-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T13:14:50Z","timestamp":1630156490000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-021-00200-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1186\/s43044-021-00200-6","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"25 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no participants\/patients involved; hence, consent to participate is not applicable. The Institutional Ethics Committee, PGIMER, INT\/IEC\/2021\/SP2-761, dated 3\/5\/2021) approves of submission of this article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no conflict of interest of any of the authors regarding its publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}